CRS

An insight into novel third-generation TLR2 co-stimulatory CAR-T cells 1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
Targetting cancer with allogeneic NK cell therapies 3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
Management of CAR-T related side effects 1:50
Management of CAR-T related side effects
Ibrahim Yakoub-Agha • 4 Feb 2021
Cytopenias post-CAR T-cell therapy 4:10
Cytopenias post-CAR T-cell therapy
Ibrahim Yakoub-Agha • 4 Feb 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias 3:50
CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias
Marion Subklewe • 11 Feb 2021
The content of VJRegenMed is intended for healthcare professionals